UBS
UBS | NYSE
$47.61
-$0.70 (-1.45%)
At close: Nov 16, 2026, 4:00 PM ET
$47.61
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:00 PM ET
UBS Company Profile
Company profile explainedCompany Profile
UBS Group AG, a financial services giant headquartered in Zurich, Switzerland, since its founding in 1862 (and known as UBS AG until its name change in December 2014), delivers a comprehensive range of financial advice and solutions to a global clientele of private individuals, institutions, and corporations. The firm structures its operations across four primary business segments: The Global Wealth Management division caters specifically to affluent and ultra-high-net-worth clients. It provides sophisticated investment guidance, various lending products, including mortgages and securities-based loans, and extensive planning services encompassing estate and wealth management, philanthropy, corporate and banking services, and family advisory. Through its Personal & Corporate Banking arm, UBS supports individual clients with essential banking services like deposits, cards, and digital platforms, alongside financing, investment opportunities, and retirement solutions. For corporate and institutional clients, this division furnishes a wide array of solutions, spanning equity and debt capital market activities, syndicated and structured credit facilities, private placements, leasing, traditional financing, international trade and export finance, global custody, and transactional banking for payments and liquidity management. The Asset Management division specializes in a broad spectrum of investment strategies, encompassing equities, fixed income, hedge funds, real estate, and private market assets. It also crafts bespoke multi-asset solutions and offers expert advisory and fiduciary services, including multi-manager hedge fund solutions. Finally, the Investment Bank offers strategic counsel to clients on significant business ventures and assists them in securing capital for their operations. It facilitates the trading, sale, and financing of securities across global capital markets, while also aiding clients in risk management and liquidity optimization, and provides distinctive insights and research on key financial markets and various securities.
Key Executives
| Name | Position |
|---|---|
| Sergio Ermotti | Group Chief Executive Officer & President of the Group Executive Board |
| Todd Tuckner | Group Chief Financial Officer & Member of Executive Board |
| Barbara Levi | Group General Counsel & Member of Group Executive Board |
| Beatriz Martin Jimenez | Group COO, Head of Non-Core & Legacy, President of EMEA and Member of Executive Board |
| George Athanasopoulos | Co-President Investment Bank & Member of Executive Board |
| Iqbal Khan | President of UBS Asia-Pacific, Co-President Global Wealth Management & Member of Group Executive Board |
| Marco Illy | Co-President of the Investment Bank & Member of Executive Board |
| Robert Karofsky | President of UBS Americas, Co-President Global Wealth Management & Member of GEB |
| Sabine Keller-Busse | President UBS Switzerland, President of Personal & Corporate Banking and Member of the GEB |
| Stefan Seiler | Head of Group HR & Corp. Services, Security and Member of the Executive Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 29, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 29, 2026 | 6-K | Filing |
| Oct 28, 2026 | 6-K | Filing |
| Oct 28, 2026 | 6-K | Filing |
| Oct 28, 2026 | 6-K | Filing |
| Oct 28, 2026 | 6-K | Filing |
| Oct 28, 2026 | 6-K | Filing |
| Oct 06, 2026 | 11-K/A | [Amend] Filing |
| Oct 06, 2026 | 11-K/A | [Amend] Filing |
UBS
| Country | Switzerland |
| IPO Date | May 16, 2000 |
| Industry | Banks - Diversified |
| Sector | Financial Services |
| Employees | 103,177 |
| CEO | Sergio Ermotti |
Stock Details
| Ticker Symbol | UBS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001610520 |
| CUSIP Number | H42097107 |
| ISIN Number | CH0244767585 |
| SIC Code | 6021 |
Recent News
- 12 hours ago / prnewswire.comTI CEO Haviv Ilan to speak at UBS investor conference
- 12 hours ago / seekingalpha.comSepterna, Inc. (SEPN) Presents at UBS Global Biopharma Conference 2026 Transcript
- 12 hours ago / seekingalpha.comADARx Pharmaceuticals, Inc. (ADRX) Presents at UBS Global Biopharma Conference 2026 Transcript
- 13 hours ago / seekingalpha.comJade Biosciences, Inc. (JBIO) Presents at UBS Global Biopharma Conference 2026 Transcript
- 3 days ago / businesswire.comThermo Fisher Scientific to Participate in UBS 2026 CEO Call Series on November 19, 2026
- 3 days ago / fool.comUBS Thinks Rivian Stock Can Hit $17. Is It a Buy?
- 4 days ago / businesswire.comUBS Announces Redemption of Ten ETNs
- 4 days ago / businesswire.comChime to Participate in UBS Global Technology and AI Conference
- 4 days ago / globenewswire.comRoyalty Pharma to present at the UBS Global Biopharma Conference
- 4 days ago / fool.comRivian Just Earned a Buy Rating. Is Wall Street Seeing a Turning Point?
Add to Watchlist
Select watchlists to add or remove UBS